CRISPR Therapeutics Nominates Addition to Board of Directors
CRISPR Therapeutics, a leading biopharmaceutical firm dedicated to pioneering gene-based treatments for severe illnesses, has unveiled its proposal to appoint Christian Rommel, Ph.D., to its Board of Directors during the…
Bimekizumab Phase 3: Sustained Improvements in Hidradenitis Suppurativa
UCB, a global biopharmaceutical company, has unveiled the findings of 48-week post-hoc analyses derived from pooled Phase 3 data originating from the BE HEARD I and BE HEARD II trials.…
AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024
Amgen Unveils New Research on Otezla® (Apremilast) at AAD 2024 Amgen, a leader in biotechnology, has disclosed fresh findings from the Phase 3 SPROUT trial, investigating Otezla® (apremilast) in children…
Wegovy® Approved in US to Lower Cardiovascular Risk in Overweight or Obese Individuals with Existing Heart Conditions
Novo Nordisk has announced today that the US Food and Drug Administration (FDA) has granted approval for an expanded label for Wegovy®. This approval, based on a supplemental New Drug…
A First-of-Its-Kind Study Shows Skin Improvement in Over Two-Thirds of People with Atopic Dermatitis and Skin of Color Using Lebrikizumab
Eli Lilly and Company (NYSE: LLY) has disclosed findings from a pioneering investigation into lebrikizumab, tailored specifically for individuals with skin of color grappling with moderate-to-severe atopic dermatitis, commonly known…
FDA to Host Advisory Committee Meeting on Donanemab’s TRAILBLAZER-ALZ 2 Study
Eli Lilly and Company (NYSE: LLY) has announced that the U.S. Food and Drug Administration (FDA) plans to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory…
Mirum Pharmaceuticals Scheduled to Attend Upcoming Investor Conferences
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading biopharmaceutical firm specializing in the discovery, acquisition, development, and distribution of innovative therapies for rare and orphan diseases, has revealed its participation in…
Oragenics, Inc. Readies Phase II Clinical Trials for Concussion Treatment Drug
Oragenics, Inc. (NYSE American: OGEN), a company dedicated to developing innovative intranasal pharmaceuticals for neurological disorders, has revealed its readiness to embark on the final stages of GMP manufacturing and…
Gossamer Bio’s 2023 Financial Report and Business Update
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on seralutinib for pulmonary arterial hypertension (PAH) treatment, reported its financials for Q4 and full-year 2023 and updated on business…
Alnylam’s KARDIA-2 Study Shows Zilebesiran Adds Significant Blood Pressure Reduction
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a pioneer in RNAi therapeutics, has announced positive results from the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT)…
Argonaut Manufacturing Services Boosts Aseptic Pharma Filling with $45M Investment
Argonaut Manufacturing Services Secures $45M Funding for Expanded Pharma Fill / Finish Facility Argonaut Manufacturing Services, a prominent contract development and manufacturing organization in the biopharma and life sciences sectors,…
Aktana Unveils Advanced Omnichannel Tools for Med-Tech Firms
Aktana Unveils “Aktana for MedTech” to Revolutionize HCP Engagement Aktana, the forefront in intelligent customer engagement for global life sciences and the medical sector, has introduced “Aktana for MedTech.” This…